Bristol-Myers Squibb: Prostatic Neoplasms trials

The registry lists 29 Prostatic Neoplasms studies with Bristol-Myers Squibb as lead sponsor. 2 are open to participants now and 13 have results posted.

Phase 1 12Phase 2 15Phase 3 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• RYZ711 Diagnostic Platform StudyNot yet recruitingNCT07862582Phase 1/2
• A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate CancerRecruitingNCT06067841Phase 1
• A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate CancerTerminatedNCT05169684Phase 2Results posted
• A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate CancerCompletedNCT04100018Phase 3Results posted
• An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate CancerCompletedNCT03338790Phase 2Results posted
• A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)CompletedNCT02985957Phase 2Results posted
• Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy NaiveCompletedNCT02279862Phase 2Results posted
• Phase 3 Study of Immunotherapy to Treat Advanced Prostate CancerCompletedNCT01057810Phase 3Results posted
• Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate CancerCompletedNCT00988208Phase 3Results posted
• Study of Immunotherapy to Treat Advanced Prostate CancerCompletedNCT00861614Phase 3Results posted
• Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate CancerCompletedNCT00744497Phase 3Results posted
• A Study of MDX-1106 in Patients With Selected Refractory or Relapsed MalignanciesCompletedNCT00441337Phase 1Results posted
• Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate CancerCompletedNCT00439270Phase 1/2Results posted
• Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate CancerCompletedNCT00385580Phase 2Results posted
• Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate CancerCompletedNCT00323882Phase 1/2Results posted
• A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate CancerActive, not recruitingNCT06764485Phase 3
• A Study of CC-90011 and Comparators in Participants With Prostate CancerCompletedNCT04628988Phase 1
• Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate CancerCompletedNCT04428788Phase 1
• Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.CompletedNCT01353625Phase 1
• A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate CancerCompletedNCT00644488Phase 1
• Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer TumorsTerminatedNCT00511576Phase 1
• ABI-008 Trial in Patients With Hormone-refractory Prostate CancerCompletedNCT00477529Phase 1/2
• A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate CancerCompletedNCT00326586Phase 1
• A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.TerminatedNCT00179738Phase 2
• A Research Study for Patients With Prostate CancerCompletedNCT00106418Phase 2
• Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228CompletedNCT00106301Phase 2
• Study of KOS-862 (Epothilone D) in Metastatic Prostate CancerTerminatedNCT00104130Phase 2
• Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)CompletedNCT00072722Phase 2
• Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate CancerCompletedNCT00050596Phase 2